Research & Development
Celltrion signs supply deals for its COVID-19 antibody therapy in Europe
30 November 2021 -

Celltrion Healthcare (Kosdaq:091990), the marketing and distribution arm of South Korean biopharmaceutical company Celltrion (KRX:068270), has signed supply deals for its monoclonal antibody to treat COVID-19 with nine European countries, Reuters news agency reported on Tuesday.

Earlier this month, the European Commission had approved Celltrion's antibody therapy Regkirona, granting marketing authorisation for adults with COVID-19 who are at increased risk of progressing to a severe condition.

In a statement, the company said that the first batch of 50,000 doses will be shipped to Europe this year adding that it in talks with 47 other nations including in Asia, Central and South America and the Middle East.

The company's antibody treatment was initially approved in South Korea and has been administered to around 25,000 local COVID-19 patients as of last week, Reuters added.



Related Headlines